큐라클
Financials
Valuation Metrics
큐라클's Market Cap is ₩2056B. At end of 2025 it was ₩1580B. Ranked #805 of 2,436 in KR market (top 33%), #365 of 1,649 on KOSDAQ (top 22%), #88 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 38%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 205.62B KRW | KR#805/2,436 Sec#88/234 |
| Revenue | 7.1M KRW | KR#2,403/2,436 Sec#229/234 |
| Net Income | -17.13B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 55.20B KRW | KR#2,143/2,436 Sec#190/234 |
| Net Assets | 41.62B KRW | KR#2,003/2,436 Sec#175/234 |
| Employees | 32 | KR#2,166/2,436 Sec#199/234 |
| Value | ||
| P/B | 4.94x | KR#2,235/2,436 Sec#185/234 |
| P/S | 28954.14x | KR#2,420/2,436 Sec#229/234 |
| FCF Yield | -6.54% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -41.17% | KR#2,235/2,436 Sec#191/234 |
| ROA | -31.04% | KR#2,309/2,436 Sec#203/234 |
| Op. Margin | -223249.99% | KR#2,402/2,436 Sec#228/234 |
| Revenue Growth | -99.56% | KR#2,348/2,436 Sec#213/234 |
| Financial Health | ||
| Debt Ratio | 132.63% | KR#899/2,436 Sec#105/234 |
| Total Debt | 14.77B KRW | KR#1,482/2,436 Sec#130/234 |
| FCF | -13.45B KRW | KR#1,800/2,436 Sec#161/234 |
| Cash | 5.05B KRW | KR#1,983/2,436 Sec#181/234 |
| Current Ratio | 2.10x | KR#891/2,436 Sec#102/234 |
| Performance | ||
| 1Y Return | 109.01% | KR#115/2,436 Sec#12/234 |
| 1M Return | -20.00% | KR#2,194/2,436 Sec#217/234 |
| From 52W High | -55.28% | KR#1,453/2,436 Sec#124/234 |
| 1Y MDD | -63.12% | KR#1,594/2,436 Sec#130/234 |
| Trading | ||
| Volume | 140,539 shares | KR#751/2,436 Sec#73/234 |
| Foreign Own. | 1.57% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -913 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,898 KRW | KR#2,055/2,436 Sec#171/234 |
Company Info
Established in 2016, this company is a specialized bio-venture focusing on research and development of therapeutics for endothelial dysfunction, specially listed on KOSDAQ in 2021. It builds an innovative new drug pipeline and conducts research and development based on its proprietary new drug development platforms, Solvadis and Eagles. In 2024, Rivasterat demonstrated vision improvement in a US Phase 2a clinical trial, while CU01 is expanding its portfolio through joint research and development and completion of domestic Phase 2b patient recruitment in 2025. Curacle, established in 2016, is headquartered in Seoul Metropolitan City, Seocho-gu.